Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Takeda Oncology.
Oncology Consultations®: Challenging the Experts on How They Treat and Individualize Care in NSCLC with ALK Inhibitors
Release Date: October 26, 2021
Expiration Date: October 26, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Takeda Oncology.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply evolving testing strategies to decision making, and ultimately therapeutic selection for frontline and subsequent management of patients with advanced ALK-positive NSCLC
- Explain recent evidence on ALK inhibitor approaches from trials that evaluated these strategies among patients with advanced NSCLC in front-line and relapsed disease settings
- Outline sequencing strategies for patients with advanced ALK-positive NSCLC to address treatment resistance and manage brain metastases
- Create preemptive strategies to mitigate and manage adverse events associated with ALK inhibitors in multiple lines of care among patients with advanced NSCLC
Faculty, Staff, and Plannrs’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
Faculty
Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Associate Professor of Medicine
Massachusetts General Hospital
Harvard Medical School
Boston, MA
Disclosures: Consultant: Bristol Myers Squibb, Genentech, Ariad/Takeda, Loxo, Pfizer, Incyte, Novartis, Merck, Agios, Amgen, Jounce, Karyopharm, GlydeBio, EMD Serono, Mirati, AstraZeneca, Regeneron, Oncorus, Helsinn, Jounce, Array, and Clovis Oncology; Research Support: Novartis, Genentech/Roche, and Ariad/Takeda, Tesaro, Moderna, Blueprint, Scholar Rock, Bristol Myers Squibb, Jounce, Array, Adaptimmune, Novartis, Genentech/Roche, Alexo and Merck; Other: Immediate faculty member who is an employee and owns stock in Ironwood Pharmaceuticals.
Assistant Professor
Upper Aerodigestive Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD
Disclosures: Consultant: Takeda
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.